Search results
Results From The WOW.Com Content Network
Inovio Pharmaceuticals Inc (NASDAQ:INO) reported its latest quarterly earnings results after the bell Wednesday, with revenue and earnings rising year-over-year. The pharmaceutical company ...
Inovio's net loss for the third quarter of 2024 was $25.2 million, or $0.89 per share, basic and dilutive, compared to a net loss of $33.9 million, or $1.52 per share, basic and dilutive, for the ...
Inovio Pharmaceuticals Inc (NASDAQ: INO) shareholders are suing the company in U.S. District Court alleging the vaccine maker misled investors by saying it came up with a coronavirus vaccine ...
Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO) Q2 2024 Earnings Call Aug 08, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants
Inovio Pharmaceuticals (INO) soared 5% in Tuesday’s after-market trading after the company announced positive interim data from a Phase 1/2a trial of DNA vaccine INO-4700 for MERS coronavirus ...
[7] [18] Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June. [5] In April 2020, Inovio began a Phase I trial of the COVID-19 vaccine candidate, INO-4800. [19]
On 26 August 2021 Inovio's global Phase 3 efficacy trial receives authorization to proceed from Brazil. [10] On 26 October 2021 The World Health Organization launched a Global Covid-19 Trial termed as the Solidarity Trial Vaccines. Inovio INO-4800 was chosen as the first DNA Vaccine to be introduced in the largest vaccine trial in history.
Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading. Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates